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Role of protein kinase Cα α α α α and G i α α α α α in regulating cPLA 2 activity by peroxynitrite in pulmonary endothelium Sajal Chakraborti, Sudip Das and Tapati Chakraborti Department of Biochemistry and Biophysics, University of Kalyani, Kalyani 741235, West Bengal, India
We determined the role of protein kinase Ca (PKCα) and Gia in regulating cytosolic phospholipase A 2 (cPLA 2 ) activity in bovine pulmonary artery endothelial cell membrane under peroxynitrite (ONOO -) stimulation. Treatment of bovine pulmonary artery endothelial cells with ONOO -markedly stimulate the cell membrane associated protease activity, PKC activity and PLA 2 activity. ONOO -significantly increases (Ca
2+
)i in the cells, and pretreatment with the intracellular Ca 2 chelator BAPTA-AM prevents the increase in (Ca
) I, protease activity, PKC activity and PLA 2 activity in the cell membrane. Pretreatment of the cells with arachidonyltrifluoromethylketone (AACOCF 3 ) (a cPLA 2 inhibitor) prevents ONOO -stimulated cPLA 2 activity without producing a significant alteration in the protease activity. Pretreatment with vitamin E and aprotinin prevents ONOO -induced increase in the protease activity, PKC activity, and cPLA 2 activity in the cell membrane. Pretreatment with the PKC inhibitor calphostin C prevents ONOO -caused increase in PKC activity and cPLA 2 activity in the cell membrane. An immunoblot study of the cell membrane isolated from the ONOO -treated cells with polyclonal PKCa antibody elicited an increase in the 80kDa immunoreactive protein band along with an additional 47kDa immunoreactive fragment. An immunoblot study with antinitrotyrosine antibody revealed that ONOO -induces nitration of tyrosine residues in PKCα. Pretreatment of the cells with aprotinin abolished the 47kDa immunoreactive fragment in the immunoblot. An immunoblot study of the endothelial cell membrane with polyclonal cPLA 2 antibody revealed that treatment of the cells with ONOO -markedly increases the cPLA 2 immunoreactive protein profile in the membrane. Pretreatment of the endothelial cells with G 0 6976 (a PKCα inhibitor) prevents the increase in PKC activity and cPLA 2 activity in the cell membrane under ONOO -triggered condition. It, therefore, appears from the present study that treatment of the cells with ONOO -causes an increase in the protease activity, and that plays an important role in activating PKCα, which subsequently stimulates cPLA 2 activity without significantly altering (Ca
) I , protease activity and PKC activity in the cell membrane. Treatment of the cells with ONOO -causes phosphorylation of G i a in the cell membrane, and pretreatment with G 0 6976 prevents its phosphorylation. These observations suggest existence of a pertussis toxin sensitive G protein-mediated mechanism for activation of cPLA 2 by ONOO -in bovine pulmonary artery endothelial cell membrane, which is regulated by PKCα dependent phosphorylation and sensitive to aprotinin for its inhibition.
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Modulatory effect of nitric oxide on Endothelin-1-induced signaling and hypertrophy
Ashok K. Srivastava
Research Centre, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada Nitric oxide (NO) is not only a vasodilator but also serves as an anti-mitogenic and antihypertrophic agent for growth factors and vasoactive peptides such as endothelin-1 (ET-1) in vascular smooth muscle cells (VSMCs). However, the mechanism by which NO exerts its anti-mitogenic and anti-hypertrophic effects remains unknown. Here we demonstrated that treatment of A-10 VSMCs with S-nitroso-Nacetylpenicillamine (SNAP) or sodium nitroprusside (SNP), two NO donors, attenuated the ET-1-enhanced phosphorylation of several key components of growth promoting and hypertrophic signaling pathways such as ERK1/2, PKB and Pyk2. On the other hand, the inhibition of the endogenous NO generation by using N-nitro-L-arginine methyl ester (L-NAME), a NO synthase inhibitor, potentiated the ET-1-induced phophosphorylation of these signaling components. Since, NO mediates its effect principally through a cyclic GMP/soluble guanylyl cyclase (sGC) pathway, we also investigated the role of these molecules in NO action. 8-Br-cGMP, a non-metabolizable and cell permeable analogue of cGMP, exhibited a similar effect as NO donor, and pharmacological blockage of sGC, reversed the inhibitory effect of NO on ET-1-induced responses. SNAP treatment also decreased the protein synthesis induced by ET-1. Taken together, these data demonstrate that NO, in a cGMP-dependent manner, attenuated ET-1-induced signaling events and hypertrophic responses. It may be suggested that suppression of ET-1 signaling pathways by NO contributes towards its anti-mitogenic and anti-hypertrophic potential. 
